[go: up one dir, main page]

MX2014002486A - Compuestos y composiciones como inhibidores de cinasa pdgfr. - Google Patents

Compuestos y composiciones como inhibidores de cinasa pdgfr.

Info

Publication number
MX2014002486A
MX2014002486A MX2014002486A MX2014002486A MX2014002486A MX 2014002486 A MX2014002486 A MX 2014002486A MX 2014002486 A MX2014002486 A MX 2014002486A MX 2014002486 A MX2014002486 A MX 2014002486A MX 2014002486 A MX2014002486 A MX 2014002486A
Authority
MX
Mexico
Prior art keywords
compounds
kinase inhibitors
compositions
pdgfr
pdgfr kinase
Prior art date
Application number
MX2014002486A
Other languages
English (en)
Inventor
Valentina Molteni
Jon Loren
Vince Yeh
Xiaolin Li
Fang Liang
Michael Gibney
Duncan Shaw
Sarah Lewis
Vikki Furminger
Ashley Mitchell Berman
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2014002486A publication Critical patent/MX2014002486A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona compuestos y composiciones farmacéuticas de los mismos, los cuales son útiles como inhibidores de cinasa de proteína, así como los métodos para utilizar tales compuestos con el fin de tratar, disminuir, o prevenir una condición asociada con una actividad de cinasa anormal o mal regulada. En algunas modalidades, la invención proporciona métodos para utilizar estos compuestos con el fin de tratar, disminuir, o prevenir las enfermedades o los trastornos que involucren una activación anormal de las cinasas PDGFR (PDGFRa, PDGFRß) o de las cinasas c-kit y PDGFR (PDGFRa, PDGFRß).
MX2014002486A 2011-09-01 2012-08-31 Compuestos y composiciones como inhibidores de cinasa pdgfr. MX2014002486A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530056P 2011-09-01 2011-09-01
US201261674999P 2012-07-24 2012-07-24
PCT/US2012/053498 WO2013033620A1 (en) 2011-09-01 2012-08-31 Compounds and compositions as pdgfr kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2014002486A true MX2014002486A (es) 2014-12-08

Family

ID=46964018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002486A MX2014002486A (es) 2011-09-01 2012-08-31 Compuestos y composiciones como inhibidores de cinasa pdgfr.

Country Status (11)

Country Link
US (1) US20140206682A1 (es)
EP (1) EP2751107A1 (es)
JP (1) JP2014525462A (es)
KR (1) KR20140105433A (es)
CN (1) CN104039783A (es)
AU (1) AU2012301675A1 (es)
BR (1) BR112014004465A2 (es)
CA (1) CA2845798A1 (es)
EA (1) EA201490542A1 (es)
MX (1) MX2014002486A (es)
WO (1) WO2013033620A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CA2845169C (en) 2011-09-01 2022-04-19 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SMT202200229T1 (it) 2011-10-03 2022-07-21 Modernatx Inc Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
HK1207306A1 (en) 2012-04-02 2016-01-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015082411A1 (de) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Aryl- und hetaryl-substituierte imidazo[1,2-a]pyridin-3-carboxamide und ihre verwendung
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
EP3852728B1 (en) 2018-09-20 2024-09-18 ModernaTX, Inc. Preparation of lipid nanoparticles and methods of administration thereof
AU2020403681A1 (en) 2019-12-13 2022-06-30 Nippon Shinyaku Co., Ltd. Compound and composition as pdgf receptor kinase inhibitor
WO2022016021A1 (en) 2020-07-15 2022-01-20 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
TW202237097A (zh) 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法
US20240109917A1 (en) * 2020-12-23 2024-04-04 Actelion Pharmaceuticals Ltd Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
WO2022165402A1 (en) * 2021-02-01 2022-08-04 Blueprint Medicines Corporation Inhibitors of protein kinase a
US20250059174A1 (en) * 2023-08-09 2025-02-20 Enanta Pharmaceuticals, Inc. Pharmaceutical Compounds and Compositions as C-Kit Kinase Inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004001903A2 (en) 2002-06-20 2003-12-31 Beacon Looms, Inc. Knitted electrical conductor fabric
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US20110046127A1 (en) * 2007-11-08 2011-02-24 Paolo Pevarello Imidazopyridazines for Use as Protein Kinase Inhibitors
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof

Also Published As

Publication number Publication date
BR112014004465A2 (pt) 2017-03-28
JP2014525462A (ja) 2014-09-29
EP2751107A1 (en) 2014-07-09
KR20140105433A (ko) 2014-09-01
CA2845798A1 (en) 2013-03-07
WO2013033620A1 (en) 2013-03-07
US20140206682A1 (en) 2014-07-24
EA201490542A1 (ru) 2014-08-29
CN104039783A (zh) 2014-09-10
AU2012301675A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
PH12014500351B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
SG194718A1 (en) Novel compounds as modulators of protein kinases
MY169987A (en) Selective pi3k delta inhibitors
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
MX2013012981A (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
WO2013155465A8 (en) Substituted xanthine derivatives
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal